Abstract
Background: CYP1A1 and CYP2D6 are important genes encoding enzymes involved in the metabolism of toxic chemicals and carcinogens. However, inconclusive results for the association between CYP1A1 and CYP2D6 polymorphisms and the risk of head and neck squamous cell carcinoma (HNSCC) have been reported. We conducted a meta-analysis to evaluate the association of CYP1A1 and CYP2D6 polymorphisms with the risk of HNSCC. Methods: A database search yielded 19 relevant studies. 3 polymorphisms were included in the meta-analysis: CYP1A1, CYP2D6*4 and CYP2D6*10. Random or fixed effect models were used in the analysis. Results: The CYP1A1 polymorphism was associated with HNSCC (for m1m1 vs. m1m2: odds ratio (OR) = 1.26, 95% confidence interval (CI) = 1.030-1.542, pheterogeneity = 0.025; for the recessive model: OR = 1.316, 95% CI = 1.065-1.625, pheterogeneity = 0.001). The analysis showed evidence for association between the CYP2D6*4 polymorphism and HNSCC in Asian populations; however, negative results were also observed in other models. A significant association was also observed between CYP2D6*10 polymorphism and HNSCC risk. Conclusions: The current study demonstrates that the CYP1A1 and CYP2D6 polymorphisms are associated with susceptibility to both development and progression of HNSCC.
Journal Section:
Original Article
References
1.
Hunter KD, Parkinson EK, Harrison PR: Profiling early head and neck cancer. Nat Rev Cancer 2005;5:127-135.
[PubMed]
2.
Blot WJ, McLaughlin JK, Winn DM, et al.: Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 1988;48:3282-3287.
[PubMed]
3.
Lewin F, Norell SE, Johansson H, et al.: Smoking tobacco, oral snuff, and alcohol in the etiology of squamous cell carcinoma of the head and neck: A population-based case-referent study in Sweden. Cancer 1998;82:1367-1375.
[PubMed]
4.
Cascorbi I, Brockmoller J, Roots I: A c4887a polymorphism in exon 7 of human CYP1A1: Population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res 1996;56: 4965-4969.
[PubMed]
5.
Bartsch H, Nair U, Risch A, et al.: Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev 2000;9:3-28.
[PubMed]
6.
Nakachi K, Hayashi S, Kawajiri K, Imai K: Association of cigarette smoking and CYP1A1 polymorphisms with adenocarcinoma of the lung by grades of differentiation. Carcinogenesis 1995;16:2209-2213.
[PubMed]
7.
Park JY, Muscat JE, Ren Q, et al.: CYP1A1 and GSTM1 polymorphisms and oral cancer risk. Cancer Epidemiol Biomarkers Prev 1997;6:791-797.
[PubMed]
8.
Taioli E, Trachman J, Chen X, et al.: A CYP1A1 restriction fragment length polymorphism is associated with breast cancer in African-American women. Cancer Res 1995;55:3757-3758.
[PubMed]
9.
Morita S, Yano M, Tsujinaka T, et al.: Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to head-and-neck squamous-cell carcinoma. Int J Cancer 1999;80:685-688.
[PubMed]
10.
Matthias C, Bockmuhl U, Jahnke V, et al.: The glutathione S-transferase GSTP1 polymorphism: Effects on susceptibility to oral/pharyngeal and laryngeal carcinomas. Pharmacogenetics 1998;8: 1-6.
[PubMed]
11.
Smith CA, Gough AC, Leigh PN, et al.: Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 1992;339: 1375-1377.
[PubMed]
12.
Wolf CR, Smith CA, Bishop T, et al.: CYP2D6 genotyping and the association with lung cancer susceptibility. Pharmacogenetics 1994;4:104-106.
[PubMed]
13.
Caporaso N, Hayes RB, Dosemeci M, et al.: Lung cancer risk, occupational exposure, and the debriso quine metabolic phenotype. Cancer Res 24 1989;49:3675-3679.
[PubMed]
14.
Hirvonen A, Husgafvel-Pursiainen K, Anttila S, et al.: PCR-based CYP2D6 genotyping for finnish lung cancer patients. Pharmacogenetics 1993;3: 19-27.
[PubMed]
15.
Agundez JA, Ledesma MC, Benitez J, et al.: CYP2D6 genes and risk of liver cancer. Lancet 1995;345:830-831.
[PubMed]
16.
Shukla P, Gupta D, Pant MC, Parmar D: CYP 2D6 polymorphism: A predictor of susceptibility and response to chemoradiotherapy in head and neck cancer. J Cancer Res Ther 2012;8:40.
[PubMed]
17.
Cochran WG: The combination of estimates from different experiments. Biometrics 1954;10:101-129.
18.
Colditz GA, Burdick E, Mosteller F: Heterogeneity in meta-analysis of data from epidemiologic studies: A commentary. Am J Epidemiol 1995;142: 371-382.
[PubMed]
19.
Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560.
[PubMed]
20.
Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-748.
[PubMed]
21.
DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
[PubMed]
22.
Singh AP, Shah PP, Ruwali M, et al.: Polymorphism in cytochrome P4501A1 is significantly associated with head and neck cancer risk. Cancer Invest 2009;27:869-876.
[PubMed]
23.
Chatterjee S, Chakrabarti S, Sengupta B, et al.: Prevalence of CYP1A1 and GST polymorphisms in the population of Northeastern India and susceptibility of oral cancer. Oncol Res 2009;17:397-403.
[PubMed]
24.
Shukla D, Dinesh Kale A, Hallikerimath S, et al.: Genetic polymorphism of drug metabolizing enzymes (GSTM1 and CYP1A1) as risk factors for oral premalignant lesions and oral cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2012;156:253-259.
[PubMed]
25.
Kao S-Y, Wu C-H, Lin S-C, et al.: Genetic polymorphism of cytochrome P4501A1 and susceptibility to oral squamous cell carcinoma and oral pre-cancer lesions associated with smoking/betel use. J Oral Pathol Med 2002;31:505-511.
[PubMed]
26.
Tanimoto K, Hayashi S, Yoshiga K, Ichikawa T: Polymorphisms of the CYP1A1 and GSTM1 gene involved in oral squamous cell carcinoma in association with a cigarette dose. Oral Oncol 1999; 35:191-196.
[PubMed]
27.
Cury NM, Russo A, Galbiatti AL, et al.: Polymorphisms of the CYP1A1 and CYP2E1 genes in head and neck squamous cell carcinoma risk. Mol Biol Rep 2012;39:1055-1063.
[PubMed]
28.
Marques CF, Koifman S, Koifman RJ, et al.: Influence of CYP1A1, CYP2E1, GSTM3 and NAT2 genetic polymorphisms in oral cancer susceptibility: Results from a case-control study in Rio de Janeiro. Oral Oncol 2006;42:632-637.
[PubMed]
29.
Lucas D, Menez C, Floch F, et al.: Cytochromes P4502E1 and P4501A1 genotypes and susceptibility to cirrhosis or upper aerodigestive tract cancer in alcoholic Caucasians. Alcohol Clin Exp Res 1996;20:1033-1037.
[PubMed]
30.
Matthias C, Bockmühl U, Jahnke V, et al.: Polymorphism in cytochrome p450 CYP2D6, CYP1A1, CYP2E1 and glutathione S-transferase, GSTM1, GSTM3, GSTT1 and susceptibility to tobacco-related cancers: Studies in upper aerodigestive tract cancers. Pharmacogenetics 1998;8:91-100.
[PubMed]
31.
Ruwali M, Parmar D: Association of functionally important polymorphisms in cytochrome P450s with squamous cell carcinoma of head and neck. Indian J Exp Biol 2010;48:651-665.
[PubMed]
32.
Anantharaman D, Chaubal PM, Kannan S, et al.: Susceptibility to oral cancer by genetic polymorphisms at CYP1A1, GSTM1 and GSTT1 loci among Indians: Tobacco exposure as a risk modulator. Carcinogenesis 2007;28:1455-1462.
[PubMed]
33.
Ko Y, Abel J, Harth V, et al.: Association of CYP1B1 codon 432 mutant allele in head and neck squamous cell cancer is reflected by somatic mutations of p53 in tumor tissue. Cancer Res 2001;61:4398-4404.
[PubMed]
34.
Topić E, Štefanović M, Ivanišević AM, et al.: The cytochrome P450 2D6 (CYP2D6) gene polymorphism among breast and head and neck cancer patients. Clin Chim Acta 2000;296:101-109.
[PubMed]
35.
Gonzalez M, Alvarez V, Pello M, et al.: Genetic polymorphism of N-acetyltransferase-2, glutathione S-transferase-m1, and cytochromes P450IIE1 and P450IID6 in the susceptibility to head and neck cancer. J Clin Pathol 1998;51:294-298.
[PubMed]
36.
Yadav SS, Ruwali M, Pant MC, et al.: Interaction of drug metabolizing cytochrome P450 2D6 poor metabolizers with cytochrome P450 2C9 and 2C19 genotypes modify the susceptibility to head and neck cancer and treatment response. Mutat Res 2010;684:49-55.
[PubMed]
37.
Worrall SF, Corrigan M, High A, et al.: Susceptibility and outcome in oral cancer: Preliminary data showing an association with polymorphism in cytochrome P450 CYP2D6. Pharmacogenetics 1998;8: 433-439.
[PubMed]
38.
Gajecka M, Rydzanicz M, Jaskula-Sztul R, et al.: CYP1A1, CYP2D6, CYP2E1, NAT2, GSTM1 and GSTT1 polymorphisms or their combinations are associated with the increased risk of the laryngeal squamous cell carcinoma. Mutat Res 2005;574:112-123.
[PubMed]
39.
Hong J-Y, Yang CS: Genetic polymorphism of cyto chrome P450 as a biomarker of susceptibility to environmental toxicity. Environ Health Perspect 1997;105:759.
[PubMed]
40.
Shimada T, Martin MV, Pruess-Schwartz D, et al.: Roles of individual human cytochrome P-450 enzymes in the bioactivation of benzo(a)pyrene, 7, 8-dihydroxy-7, 8-dihydrobenzo(a)pyrene, and other dihydrodiol derivatives of polycyclic aromatic hydrocarbons. Cancer Res 1989;49:6304-6312.
[PubMed]
41.
Hayashi S-I, Watanabe J, Nakachi K, Kawajin K: PCR detection of an A/G polymorphism within exon 7 of the CYP1A1 gene. Nucleic Acids Res 1991;19:4797-4797.
[PubMed]
42.
Landi M, Bertazzi P, Shields P, et al.: Association between CYP1A1 genotype, mRNA expression and enzymatic activity in humans. Pharmacogenetics 1994;4:242-246.
[PubMed]
43.
Zanger UM, Raimundo S, Eichelbaum M: Cytochrome P450 2D6: Overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004;369:23-37.
[PubMed]
44.
Jann MW, Cohen LJ: The influence of ethnicity and antidepressant pharmacogenetics in the treatment of depression. Drug Metabol Drug Interact 2000; 16:39-67.
[PubMed]
45.
Dick B, Küpfer A, Molnar J, et al.: Drug hydroxylation disorders (debrisoquin type) in a random sample of the Swiss population]. Schweiz Med Wochenschr 1982;112:1061.
46.
Wanwimolruk S, Patamasucon P, Lee E: Evidence for the polymorphic oxidation of debrisoquine in the Thai population. Br J Clin Pharmacol 1990; 29:244-247.
[PubMed]
47.
Abraham BK, Adithan C, Shashindran C, et al.: Genetic polymorphism of CYP2D6 in a keralite (South India) population. Br J Clin Pharmacol 2000;49:285-286.
[PubMed]
48.
Garcia-Barceló M, Chow LY, Chiu HFK, et al.: Genetic analysis of the CYP2D6 locus in a Hong Kong chinese population. Clin Chem 2000;46:18-23.
[PubMed]
© 2014 S. Karger GmbH, Freiburg
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2014
You do not currently have access to this content.
